Trial reportDrug design, development and therapy2025
Effect of Perioperative Subanesthetic Dose of Esketamine on Postoperative Recovery Quality in Patients Undergoing Laparoscopic Gastrointestinal Surgery: A Randomised, Double-Blind, Controlled Trial.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparative safety of esketamine in procedural sedation and analgesia: a systematic review and network meta-analysis.BMC anesthesiology · 2026Pooled it
- Effect of Subanesthetic Doses of Esketamine on Early Postoperative Pain Sensitivity in Patients Undergoing Salpingectomy: A Randomized Clinical Trial.Drug design, development and therapy · 2026Trial
- Esketamine for Postoperative Multimodal Analgesia in Laparoscopic Surgery: A Systematic Review and Meta-Analysis.Journal of pain research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate the effect of perioperative subanesthetic dose of esketamine on the postoperative recovery quality in patients undergoing laparoscopic gastrointestinal surgery. Methods: A total of 144 patients undergoing elective surgery for gastrointestinal tumors were selected and randomly assigned to either the esketamine group or the control group, with 72 patients in each group. Based on the standardized general anesthesia protocols, the esketamine group received an intravenous injection of esketamine at a dose of 0.2 mg/kg during the induction of anesthesia and an additional 0.2 mg/kg 30 minutes before the end of the surgery. Patient-controlled intravenous analgesia (PCIA) was administered for 48 hours, the esketamine group was treated with sufentanil (0.04 μg/kg/h) combined with esketamine (0.02 mg/kg/h) and sufentanil (0.04 μg/kg/h) was used as the control group. The scores of 40-items Quality of Recovery Scale (QoR-40) were recorded one day before surgery, one day after surgery, three days after surgery, and five days after surgery. Numerical Rating Scale (NRS) pain scores were recorded at postoperative intervals of 6 hours, 24 hours, 36 hours, and 48 hours. Levels of interleukin-6 (IL-6), tumor necrosis factor (TNF-α), and brain-derived neurotrophic factor (BDNF) in venous blood were analyzed prior to entering the operating room, upon arrival at the recovery room, and on the second postoperative day. Results: A total of 140 patients completed this study. Compared to the control group, the QoR-40 scores in the esketamine group were significantly higher at 1, 3, and 5 days post-surgery ( Conclusion: This study found that the perioperative use of subanesthetic esketamine improved early postoperative recovery quality and reduced postoperative pain levels in patients undergoing laparoscopic gastrointestinal surgery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.